JP2020521794A5 - - Google Patents

Download PDF

Info

Publication number
JP2020521794A5
JP2020521794A5 JP2019566178A JP2019566178A JP2020521794A5 JP 2020521794 A5 JP2020521794 A5 JP 2020521794A5 JP 2019566178 A JP2019566178 A JP 2019566178A JP 2019566178 A JP2019566178 A JP 2019566178A JP 2020521794 A5 JP2020521794 A5 JP 2020521794A5
Authority
JP
Japan
Prior art keywords
composition
use according
eldaphytinib
fgfr2
fgfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019566178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020521794A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/064523 external-priority patent/WO2018220206A1/en
Publication of JP2020521794A publication Critical patent/JP2020521794A/ja
Publication of JP2020521794A5 publication Critical patent/JP2020521794A5/ja
Priority to JP2023077882A priority Critical patent/JP2023113650A/ja
Withdrawn legal-status Critical Current

Links

JP2019566178A 2017-06-02 2018-06-01 胆管癌の治療のためのfgfr2阻害剤 Withdrawn JP2020521794A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023077882A JP2023113650A (ja) 2017-06-02 2023-05-10 胆管癌の治療のためのfgfr2阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17174295.0 2017-06-02
EP17174295 2017-06-02
EP18171315.7 2018-05-08
EP18171315 2018-05-08
PCT/EP2018/064523 WO2018220206A1 (en) 2017-06-02 2018-06-01 Fgfr2 inhibitors for the treatment of cholangiocarcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023077882A Division JP2023113650A (ja) 2017-06-02 2023-05-10 胆管癌の治療のためのfgfr2阻害剤

Publications (2)

Publication Number Publication Date
JP2020521794A JP2020521794A (ja) 2020-07-27
JP2020521794A5 true JP2020521794A5 (cg-RX-API-DMAC7.html) 2021-07-26

Family

ID=62555054

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019566178A Withdrawn JP2020521794A (ja) 2017-06-02 2018-06-01 胆管癌の治療のためのfgfr2阻害剤
JP2023077882A Pending JP2023113650A (ja) 2017-06-02 2023-05-10 胆管癌の治療のためのfgfr2阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023077882A Pending JP2023113650A (ja) 2017-06-02 2023-05-10 胆管癌の治療のためのfgfr2阻害剤

Country Status (16)

Country Link
US (2) US11707463B2 (cg-RX-API-DMAC7.html)
EP (1) EP3634414A1 (cg-RX-API-DMAC7.html)
JP (2) JP2020521794A (cg-RX-API-DMAC7.html)
KR (1) KR20200010505A (cg-RX-API-DMAC7.html)
CN (1) CN111050769A (cg-RX-API-DMAC7.html)
AU (1) AU2018278271B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019025056A2 (cg-RX-API-DMAC7.html)
CA (1) CA3064317A1 (cg-RX-API-DMAC7.html)
IL (1) IL271058A (cg-RX-API-DMAC7.html)
JO (1) JOP20190280A1 (cg-RX-API-DMAC7.html)
MA (1) MA49248A (cg-RX-API-DMAC7.html)
MX (1) MX2019014366A (cg-RX-API-DMAC7.html)
MY (1) MY204203A (cg-RX-API-DMAC7.html)
PH (1) PH12019502710A1 (cg-RX-API-DMAC7.html)
UA (1) UA126478C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018220206A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016022056B1 (pt) 2014-03-26 2023-04-11 Astex Therapeutics Limited Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
BR112021015686A2 (pt) * 2019-02-12 2021-10-26 Janssen Pharmaceutica N.V. Tratamento de câncer
MX2021011926A (es) * 2019-03-29 2021-11-03 Janssen Pharmaceutica Nv Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.
CA3141869A1 (en) * 2019-05-28 2020-12-03 Qed Therapeutics, Inc. Methods of treating cholangiocarcinoma
TW202114665A (zh) * 2019-08-05 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 一種吡咯并六員雜環化合物在製備治療fgfr2基因變異的腫瘤的藥物中的用途
WO2021146163A1 (en) * 2020-01-17 2021-07-22 Beta Pharma, Inc. Pyridazine and 1,2,4-triazine derivatives as fgfr kinase inhibitors
CN111596058A (zh) * 2020-05-18 2020-08-28 山东第一医科大学(山东省医学科学院) 一种检测胆管癌患者外周血循环肿瘤细胞fgfr基因突变的试剂盒及检测方法
DE102021126650A1 (de) 2021-10-14 2023-04-20 Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff
KR20250117064A (ko) 2024-01-26 2025-08-04 충북대학교 산학협력단 아무렌신 g를 유효성분으로 포함하는 담관암 예방 또는 치료용 약학적 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
WO2008118877A2 (en) * 2007-03-23 2008-10-02 The Translational Genomics Research Institute Method of diagnosing, classifying and treating endometrial cancer and precancer
GB201007286D0 (en) * 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
US9254288B2 (en) * 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
CA2898326C (en) * 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
SG11201702381QA (en) 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
EP3365335B1 (en) 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Similar Documents

Publication Publication Date Title
Di Nardo et al. Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects
Cuisset et al. Aspirin noncompliance is the major cause of “aspirin resistance” in patients undergoing coronary stenting
Perez‐Ruiz et al. A two‐stage approach to the treatment of hyperuricemia in gout: the “dirty dish” hypothesis
Gild et al. Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells
Frisch et al. Superior water maze performance and increase in fear-related behavior in the endothelial nitric oxide synthase-deficient mouse together with monoamine changes in cerebellum and ventral striatum
JP2023113650A5 (cg-RX-API-DMAC7.html)
Ji et al. Irradiation-induced hippocampal neurogenesis impairment is associated with epigenetic regulation of bdnf gene transcription
Sarin et al. Early primary prophylaxis with beta-blockers does not prevent the growth of small esophageal varices in cirrhosis: a randomized controlled trial
Wang et al. BRG1 in the nucleus accumbens regulates cocaine-seeking behavior
JP2020533381A5 (cg-RX-API-DMAC7.html)
Sieland et al. Changes in miRNA expression in patients with peripheral arterial vascular disease during moderate-and vigorous-intensity physical activity
Jurgens et al. Contribution of the subjective components of the disease activity score to the response to biologic treatment in rheumatoid arthritis
Moraska et al. Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation study–NCCTG trial N00CB
Suzuki et al. Sustained-release lidocaine sheet for pain following tooth extraction: A randomized, single-blind, dose-response, controlled, clinical study of efficacy and safety
Lee et al. Impact of postoperative hepatitis B virus reactivation in hepatocellular carcinoma patients who formerly had naturally suppressed virus
Yan et al. Clinical evaluation of the socket-shield technique for immediate implantation in the maxillary anterior region
Patrick et al. The predictive value of fall assessment tools for patients admitted to hospice care
Zhang et al. Restoring the secretory function of irradiation-damaged salivary gland by administrating deferoxamine in mice
Nielsen et al. The effect of sertindole on QTD and TPTE
Yeh et al. EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid
Kimura et al. Effects of repeated electroconvulsive shocks on dopamine supersensitivity psychosis model rats
Lin et al. Cancer-related fatigue
Mertens et al. Dental Implants in Medically Compromised Patients Undergoing or After Receiving Anti‐Resorptive or Radiotherapy: Retrospective Clinical and Radiographic Data
CN104271763B (zh) 对高强度电离放射线敏感的基因的检测方法及用所述方法检测的基因
Margolis Antihypertensive medication use in older adults at risk for hip fracture.